Literature DB >> 19528658

Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior.

Stephen D Mague1, Carolina Isiegas, Peng Huang, Lee-Yuan Liu-Chen, Caryn Lerman, Julie A Blendy.   

Abstract

A single nucleotide polymorphism (SNP) in the human mu-opioid receptor gene (OPRM1 A118G) has been widely studied for its association in a variety of drug addiction and pain sensitivity phenotypes; however, the extent of these adaptations and the mechanisms underlying these associations remain elusive. To clarify the functional mechanisms linking the OPRM1 A118G SNP to addiction and analgesia phenotypes, we derived a mouse model possessing the equivalent nucleotide/amino acid substitution in the Oprm1 gene. Mice harboring this SNP (A112G) demonstrated several phenotypic similarities to humans carrying the A118G SNP, including reduced mRNA expression and morphine-mediated antinociception. We found additional phenotypes associated with this SNP including significant reductions of receptor protein levels, morphine-mediated hyperactivity, and the development of locomotor sensitization in mice harboring the G112 allele. In addition, we found sex-specific reductions in the rewarding properties of morphine and the aversive components of naloxone-precipitated morphine withdrawal. Further cross-species analysis will allow us to investigate mechanisms and adaptations present in humans carrying this SNP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528658      PMCID: PMC2705603          DOI: 10.1073/pnas.0901800106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects.

Authors:  J Gelernter; H Kranzler; J Cubells
Journal:  Mol Psychiatry       Date:  1999-09       Impact factor: 15.992

2.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

3.  Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty.

Authors:  W-Y Chou; L-C Yang; H-F Lu; J-Y Ko; C-H Wang; S-H Lin; T-H Lee; A Concejero; C-J Hsu
Journal:  Acta Anaesthesiol Scand       Date:  2006-08       Impact factor: 2.105

4.  A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Alcohol Clin Exp Res       Date:  2004-12       Impact factor: 3.455

5.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Arch Gen Psychiatry       Date:  2007-09

6.  Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis.

Authors:  G Schulteis; A Markou; L H Gold; L Stinus; G F Koob
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

7.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.

Authors:  L Y Liu-Chen; H H Yang; S Li; J U Adams
Journal:  J Pharmacol Exp Ther       Date:  1995-06       Impact factor: 4.030

9.  An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.

Authors:  Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman
Journal:  Arch Gen Psychiatry       Date:  2008-02

10.  The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor.

Authors:  Thomas Kroslak; K Steven Laforge; Robert J Gianotti; Ann Ho; David A Nielsen; Mary Jeanne Kreek
Journal:  J Neurochem       Date:  2007-10       Impact factor: 5.372

View more
  82 in total

Review 1.  The Influence of Endogenous Opioids on the Relationship between Testosterone and Romantic Bonding.

Authors:  Davide Ponzi; Melissa Dandy
Journal:  Hum Nat       Date:  2019-03

2.  No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample.

Authors:  Momchil A Nikolov; Olga Beltcheva; Antoaneta Galabova; Anna Ljubenova; Elena Jankova; Galin Gergov; Atanas A Russev; Michael T Lynskey; Elliot C Nelson; Eleonora Nesheva; Dorita Krasteva; Philip Lazarov; Vanio I Mitev; Ivo M Kremensky; Radka P Kaneva; Alexandre A Todorov
Journal:  Drug Alcohol Depend       Date:  2011-01-31       Impact factor: 4.492

3.  Modeling neuropsychiatric disease-relevant human SNPs in mice.

Authors:  Julie A Blendy
Journal:  Neuropsychopharmacology       Date:  2011-01       Impact factor: 7.853

Review 4.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 5.  Pharmacogenetic approaches to the treatment of alcohol addiction.

Authors:  Markus Heilig; David Goldman; Wade Berrettini; Charles P O'Brien
Journal:  Nat Rev Neurosci       Date:  2011-10-20       Impact factor: 34.870

6.  Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry.

Authors:  Dina Popova; Nidhi Desai; Julie A Blendy; Zhiping P Pang
Journal:  J Neurosci       Date:  2019-05-20       Impact factor: 6.167

7.  Behavioural activation system sensitivity is associated with cerebral μ-opioid receptor availability.

Authors:  Tomi Karjalainen; Lauri Tuominen; Sandra Manninen; Kari K Kalliokoski; Pirjo Nuutila; Iiro P Jääskeläinen; Riitta Hari; Mikko Sams; Lauri Nummenmaa
Journal:  Soc Cogn Affect Neurosci       Date:  2016-04-06       Impact factor: 3.436

8.  Adult attachment style is associated with cerebral μ-opioid receptor availability in humans.

Authors:  Lauri Nummenmaa; Sandra Manninen; Lauri Tuominen; Jussi Hirvonen; Kari K Kalliokoski; Pirjo Nuutila; Iiro P Jääskeläinen; Riitta Hari; Robin I M Dunbar; Mikko Sams
Journal:  Hum Brain Mapp       Date:  2015-06-05       Impact factor: 5.038

Review 9.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

10.  Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: A pilot study.

Authors:  Eric A Woodcock; Leslie H Lundahl; Margit Burmeister; Mark K Greenwald
Journal:  Am J Addict       Date:  2015-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.